Skip to main content

Citizens JMP Sticks to Its Buy Rating for Inovio Pharmaceuticals (INO)

Tipranks - Tipranks - Thu Aug 14, 2025

Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $12.00. The company’s shares closed yesterday at $1.49.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Buchanan is an analyst with an average return of -22.0% and a 27.80% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Enanta Pharmaceuticals, and Dynavax.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inovio Pharmaceuticals with a $6.90 average price target, which is a 363.09% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $5.00 price target.

See the top stocks recommended by analysts >>

INO market cap is currently $75.93M and has a P/E ratio of -0.47.

Read More on INO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).